Stanley T. Crooke

Dr. Stanley T. Crooke

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2021 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
PDF file
SCStanley T. Crooke
Stanley T. Crooke
BBBrenda F. Baker
Brenda F. Baker
RCRosanne M. Crooke
Rosanne M. Crooke
XLXue-Hai Liang
Xue-Hai Liang

1 April 2018 in Cell Metabolism
Verified
Journal Article
Closed access
SCStanley T. Crooke
Stanley T. Crooke
JWJoseph L. Witztum
Joseph L. Witztum
CBC. Frank Bennett
C. Frank Bennett
BBBrenda F. Baker
Brenda F. Baker

1 April 2017 in Nucleic Acid Therapeutics
Verified
Journal Article
Open access
SCStanley T. Crooke
Stanley T. Crooke
In 1987, when I became interested in the notion of antisense technology, I returned to my roots in RNA biochemistry and began work to understand how oligonucleotides behave in biological systems. Since 1989, my research has focused primarily on this topic, although I have been involved in most areas of research in antisense technology. I believe that the art of excellent science is to frame large important questions that are perhaps not immediately answerable with existing knowledge and methods, and then conceive a long-term (multiyear) research strategy that begins by answering the most pressing answerable questions on the path to the long-term goals. Then, a step-by-step research pathway that will address the strategic questions posed must be implemented, adjusting the plan as new things are learned. This is the approach we have taken at Ionis. Obviously, to create antisense technology, we have had to address a wide array of strategic questions, for example, the medicinal chemistry of oligonucleotides, manufacturing and analytical methods, pharmacokinetics and toxicology, as well as questions about the molecular pharmacology of antisense oligonucleotides (ASOs). Each of these endeavors has consumed nearly three decades of scientific effort, is still very much a work-in-progress, and has resulted in hundreds of publications. As a recipient of the Lifetime Achievement Award 2016 granted by the Oligonucleotide Therapeutic Society, in this note, my goal is to summarize the contributions of my group to the efforts to understand the molecular mechanisms of ASOs.

4 June 2020 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
SCStanley T. Crooke
Stanley T. Crooke
TVTimothy A Vickers
Timothy A Vickers
XLXuehai Liang
Xuehai Liang
Antisense oligonucleotides (ASOs) interact with target RNAs via hybridization to modulate gene expression through different mechanisms. ASO therapeutics are chemically modified and include phosphorothioate (PS) backbone modifications and different ribose and base modifications to improve pharmacological properties. Modified PS ASOs display better binding affinity to the target RNAs and increased binding to proteins. Moreover, PS ASO protein interactions can affect many aspects of their performance, including distribution and tissue delivery, cellular uptake, intracellular trafficking, potency and toxicity. In this review, we summarize recent progress in understanding PS ASO protein interactions, highlighting the proteins with which PS ASOs interact, the influence of PS ASO protein interactions on ASO performance, and the structure activity relationships of PS ASO modification and protein interactions. A detailed understanding of these interactions can aid in the design of safer and more potent ASO drugs, as illustrated by recent findings that altering ASO chemical modifications dramatically improves therapeutic index.

29 April 2019 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
WSWen Shen
Wen Shen
CHCheryl L. De Hoyos
Cheryl L. De Hoyos
MMMichael T. Migawa
Michael T. Migawa
TVTimothy A. Vickers
Timothy A. Vickers
HSHong Sun
Hong Sun
SCStanley T. Crooke
Stanley T. Crooke

1 January 2021 in Journal of Biological Chemistry
Verified
Journal Article
Open access
SCStanley T. Crooke
Stanley T. Crooke
XLXuehai Liang
Xuehai Liang
BBBrenda F. Baker
Brenda F. Baker
RCRosanne M. Crooke
Rosanne M. Crooke
Antisense technology is beginning to deliver on the broad promise of the technology. Ten RNA Targeted drugs including 8 single strand antisense drugs (ASOs) and 2 double strand ASOs (siRNAs) have now been approved for commercial use and the ASOs in Phase 2/3 trials are innovative, delivered by multiple routes of administration and focused on both rare and common diseases. In fact, two ASOs are in cardiovascular outcome studies and several others in very large trials. Interest in the technology continues to grow and the field has been subject to a significant number of reviews. In this review, we focus on the molecular events that result in the effects observed and use recent clinical results involving several different ASOs to exemplify specific molecular mechanisms and specific issues. We conclude with the prospective on the technology.